This site is for healthcare professionals. If you are a member of the public or a patient then please visit our Colonoscopy site.

Reminder Service

Clinical Trials

PLENVU® achieved superior colon cleansing compared to MOVIPREP® using evening/morning dosing1

Rate of successful overall bowel preparation in the per protocol population*1

Adapted from Bisschops R, et al. 20191

PLENVU® doubled high-quality cleansing rates in the right colon vs MOVIPREP® (p<0.001)1,4

Rate of high-quality and adequate cleansing in the right colon in the mFAS population4

Adapted from DOF-PLENV-001. July 20194

ESGE recommendation

The ESGE strongly recommend using high- or low-volume PEG regimens or non-PEG-based regimens that have been clinically validated.†5

*Successful overall bowel preparation was defined as grade A or B using the Harefield Cleansing Scale.
†In patients at high risk for hydroelectrolyte disturbances, the choice of laxative should be individualised.

/: evening/morning dosing, /: morning/morning dosing, ESGE: European Society of Gastrointestinal Endoscopy, LCL: lower confidence limit, mFAS: modified full analysis set.

Study design

Real-world evidence

PLENVU® was significantly more effective than 2L and 4L PEG2

Rate of successful bowel preparation2

Adapted from Maida M, et al. 20202

PLENVU® doubled the high-quality cleansing rate in the right colon vs 2L and 4L PEG2

Rate of high-quality cleansing in the right colon2

Adapted from Maida M, et al. 20202

*Cleansing data were not available for 41 patients across the treatment arms.

All treatments were administered using afternoon/afternoon or afternoon/morning dosing.

Study design

GL-GE-PLV-2100023. July 2021.

Adverse events should be reported to your regulatory agency. Adverse events should also be reported to either your local distributor, Norgine Limited, Norgine House, Moorhall Road, Harefield, Uxbridge, Middlesex, UB9 6NS, United Kingdom or by emailing